Literature DB >> 8166288

Saturable binding of circulating peptide YY in the dorsal vagal complex of rats.

E J Hernandez1, D C Whitcomb, S R Vigna, I L Taylor.   

Abstract

The rationale for this study was to test the hypothesis that peripherally released peptide YY (PYY) acts in the vagal nuclear complex of the medulla oblongata to modulate vagal tone centrally. The objective was to determine whether circulating PYY gains access to and binds to the receptors identified in the dorsal vagal complex (DVC) under physiological conditions. Specific brain regions were microdissected after intravenous 125I-labeled PYY and 131I-labeled bovine serum albumin infusions to determine saturable accumulation of PYY in the brain and to determine if there were changes in plasma volume with large PYY infusions. Significant (P < 0.05) saturable binding was observed in the region of the brain stem containing the DVC and the pituitary. There were no significant changes in plasma volume in any region after the infusion of the excess nonradioactive PYY. We conclude that under physiological conditions circulating PYY binds to sites in the pituitary and portions of the DVC that have PYY receptors and an incomplete blood-brain barrier but does not bind to other areas that have an intact blood-brain barrier. Therefore this peripheral hormone may act centrally to modulate the digestive system and is a member of a novel class of gut hormones that function as central neuromodulators.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8166288     DOI: 10.1152/ajpgi.1994.266.3.G511

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  13 in total

Review 1.  Brainstem neuropeptides and vagal protection of the gastric mucosal against injury: role of prostaglandins, nitric oxide and calcitonin-gene related peptide in capsaicin afferents.

Authors:  Y Tache
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 2.  Neuropeptide Y Y2 receptor in health and disease.

Authors:  S L Parker; A Balasubramaniam
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

3.  Brainstem pathways responsible for oesophageal control of gastric motility and tone in the rat.

Authors:  R C Rogers; G E Hermann; R A Travagli
Journal:  J Physiol       Date:  1999-01-15       Impact factor: 5.182

4.  Area postrema lesion alters the effects of peptide YY on 2-DG-stimulated pancreatic exocrine secretion.

Authors:  X Deng; D R Guarita; M R Pedroso; P G Wood; C Kreiss; A F Sved; D C Whitcomb
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

5.  Non-specific binding and general cross-reactivity of Y receptor agonists are correlated and should importantly depend on their acidic sectors.

Authors:  M S Parker; R Sah; A Balasubramaniam; F R Sallee; O Zerbe; S L Parker
Journal:  Peptides       Date:  2010-11-30       Impact factor: 3.750

6.  PYY regulates pancreatic exocrine secretion through multiple receptors in the awake rat.

Authors:  D R Guarita; X Deng; Y B Huh; P G Wood; J R Reeve; D C Whitcomb
Journal:  Dig Dis Sci       Date:  2000-09       Impact factor: 3.199

7.  Ileal effect on blood glucose, HbA1c, and GLP-1 in Goto-Kakizaki rats.

Authors:  Henry Buchwald; Hector J Menchaca; Van N Michalek; Nestor T Bertin
Journal:  Obes Surg       Date:  2014-11       Impact factor: 4.129

8.  Neuronal activation of brain vagal-regulatory pathways and upper gut enteric plexuses by insulin hypoglycemia.

Authors:  Pu-Qing Yuan; Hong Yang
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-09       Impact factor: 4.310

9.  Modulation of inhibitory neurotransmission in brainstem vagal circuits by NPY and PYY is controlled by cAMP levels.

Authors:  K N Browning; R A Travagli
Journal:  Neurogastroenterol Motil       Date:  2009-07-20       Impact factor: 3.598

10.  Reversal by NPY, PYY and 3-36 molecular forms of NPY and PYY of intracisternal CRF-induced inhibition of gastric acid secretion in rats.

Authors:  M Gué; J L Junien; J R Reeve; J Rivier; D Grandt; Y Taché
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.